What is Merus?
Merus is a biopharmaceutical firm dedicated to the development of novel full-length bispecific and trispecific antibody therapeutics, a technology they refer to as Multiclonics®. These advanced therapeutic candidates are manufactured using standard industry processes and have demonstrated characteristics akin to conventional human monoclonal antibodies in preclinical and clinical studies, including extended half-life and low immunogenicity. The company's focus on oncology aims to address unmet needs in cancer treatment through its unique antibody engineering capabilities.
How much funding has Merus raised?
Merus has raised a total of $60M across 1 funding round:
Stock Offering
$60M
Stock Issuance/Offering (2016): $60M, investors not publicly disclosed
What's next for Merus?
The substantial enterprise-level and strategic investment Merus has garnered positions it for accelerated growth and development. This significant backing is expected to fuel the advancement of its pipeline, potentially enabling the company to progress its bispecific and trispecific antibody candidates through further clinical trials and towards commercialization. Such strategic financing often empowers companies to expand research and development efforts, scale manufacturing capabilities, and bolster their commercial infrastructure, paving the way for future breakthroughs in oncology therapeutics.
See full Merus company page
